Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cance...
Turnstone Biologics Corp. (TSBX)
Company Research
Source: GlobeNewswire
Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broa
Show less
Read more
Impact Snapshot
Event Time:
TSBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSBX alerts
High impacting Turnstone Biologics Corp. news events
Weekly update
A roundup of the hottest topics
TSBX
News
- Turnstone Biologics Corp. (NASDAQ: TSBX) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating.MarketBeat
- Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswire
- Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Turnstone Biologics Corp. (NASDAQ: TSBX) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating.MarketBeat
- Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial RunwayGlobeNewswire
TSBX
Earnings
- 3/21/24 - Beat
TSBX
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 10/11/24 - Form 8-K
- TSBX's page on the SEC website